Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EYEG AB Corporate Bond ETF (EYEG) Price, Holdings, & News Add Compare Share Share Stock Analysis Stock AnalysisDividendHeadlinesShort InterestTrends About AB Corporate Bond ETF (NASDAQ:EYEG) 30 days 90 days 365 days Advanced Chart Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get AB Corporate Bond ETF alerts:Sign Up Key Stats Today's Range$35.74▼$35.7450-Day Range$1.59▼$2.2552-Week Range$1.44▼$8.18Volume46 shsAverage Volume935,975 shsMarket Capitalization$25.01 millionAssets Under Management$24.94 millionDividend Yield1.97%Net Expense Ratio0.30%Aggregate RatingN/A ETF OverviewEyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.Read More… Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. AB Corporate Bond ETF ExpensesTypeEYEGInvestment Grade ETFsFixed Income ETFsNASDAQ ETFsAll ETFsManagement Fee0.30%0.22%0.33%0.50%0.52%Other Expenses0.00%0.12%0.26%0.41%0.53%Total Expense0.30%0.25%0.40%0.63%0.71%Fee Waiver0.00%-0.14%-0.25%-0.32%-0.57%Net Expense0.30%0.23%0.36%0.56%0.59% Receive EYEG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AB Corporate Bond ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address EYEG ETF News HeadlinesGoldman Sachs Access High Yield Corporate Bond ETF declares monthly distribution of $0.2568November 4, 2024 | msn.comVanguard ESG U.S. Corporate Bond ETF declares monthly distribution of $0.2408November 1, 2024 | msn.comTop secret Trump trades?As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”November 23, 2024 | Insiders Exposed (Ad)What Economic Factors Influence Corporate Bond Yields?October 30, 2024 | investopedia.comBUFC AB Conservative Buffer ETFOctober 27, 2024 | seekingalpha.comHigh Yield Corporate Bonds In Emerging Markets Are Red HotOctober 22, 2024 | seekingalpha.comSee More Headlines EYEG ETF - Frequently Asked Questions How were AB Corporate Bond ETF's earnings last quarter? AB Corporate Bond ETF (NASDAQ:EYEG) posted its earnings results on Thursday, August, 12th. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.07. When did AB Corporate Bond ETF IPO? AB Corporate Bond ETF (EYEG) raised $5 million in an initial public offering on Friday, February 13th 2015. The company issued 800,000 shares at $6.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO. What other stocks do shareholders of AB Corporate Bond ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that AB Corporate Bond ETF investors own include Bausch Health Companies (BHC), MannKind (MNKD), Bristol-Myers Squibb (BMY), Sorrento Therapeutics (SRNE), Idera Pharmaceuticals (IDRA), SCYNEXIS (SCYX) and Novavax (NVAX). Fund Details IssuerAllianceBernstein Fund NameAB Corporate Bond ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:EYEG Inception Date12/13/2023 Fund ManagerTimothy Kurpis, Bernd Wuebben Webwww.eyegatepharma.com Phone(781) 788-8869Fund Focus Asset ClassFixed Income BenchmarkN/A CategoryCorporate FocusInvestment Grade Development LevelBlended Development RegionGlobal Number of Holdings405 Fund Statistics Assets Under Management$24.94 million Average Daily Volume$0.00 Discount/Premium0.11% Administrator, Advisor and Custodian AdministratorState Street Bank and Trust Company AdvisorAllianceBernstein L.P. CustodianState Street Bank and Trust Company DistributorForeside Fund Services, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerJane Street Options OptionableN/A Short Interest1,100 shs Miscellaneous Outstanding Shares700,000Beta0.16 Creation Unit50,000 Creation Fee$250.00 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:EYEG) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AB Corporate Bond ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share AB Corporate Bond ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
